News | Peripheral Artery Disease (PAD) | July 02, 2018

PQ Bypass Effective in Treating Extremely Long SFA Lesions at 12 Months

DETOUR I trial presented during SVS Vascular Annual Meeting 2018 late breaking clinical trial session

PQ Bypass Effective in Treating Extremely Long SFA Lesions at 12 Months

July 2, 2018 — The PQ Bypass Detour System showed promising 12-month durability for patients with extremely long blockages in the superficial femoral artery (SFA) in new results from the DETOUR I Trial. The data were presented as a late-breaking clinical trial session at the Society for Vascular Surgery (SVS) Vascular Annual Meeting, June 20-23 in Boston, Mass. The trial enrolled lesions longer and more complex than those typically studied in SFA clinical trials, with an average lesion length of 37cm, 100 percent TASC II C/D, 96 percent chronic total occlusions (CTO) and 81 percent with moderate-to-severe calcification.

The DETOUR I trial — a prospective, single-arm, multicenter, core lab-adjudicated study — enrolled and treated 77 patients and 81 lesions. Primary and primary-assisted patency at 12 months in all lesions of the DETOUR I trial was 73 percent and 80 percent, respectively. Secondary patency was achieved in 94 percent of patients. Additional safety and effectiveness outcomes include 100 percent freedom from amputation, 99 percent freedom from acute limb ischemia, and Rutherford improvement of ≥ 2 classes in 90 percent of patients.

“The lesions treated in DETOUR I were more than just long, they were extremely long, completely blocked and severely calcified,” said Dainis Krieviņš, M.D., Ph.D., vascular surgeon and director of the Institute of Research at Pauls Stradins Clinical University Hospital, Riga, Latvia. “Endovascular devices currently approved for use on these incredibly challenging lesions have surprisingly low durability in lesions that are half the size of the average DETOUR lesion and fail approximately 40 percent of the time by the 12-month milestone. This truly highlights the need for the minimally invasive DETOUR procedure for long, complex SFA lesions.”

Percutaneous femoropopliteal bypass (the Detour procedure) is an entirely new procedure enabled by PQ Bypass’s proprietary Detour System. The Detour procedure creates a pathway with PQ Bypass’s proprietary stent grafts, originating in the SFA, traveling through the femoral vein and ending in the popliteal artery, bypassing the diseased part of the artery. The stent grafts redirect oxygen-rich blood around the blockage, restoring blood flow to the lower leg and foot of the patient.

For more information: www.pqbypass.com


Related Content

News | Cardiovascular Clinical Studies

Aug. 15, 2024 — According to a new study being presented at ACC Asia 2024 in Delhi, India, drinking over 400 mg of ...

Home August 14, 2024
Home
Videos | Cardiovascular Clinical Studies

As part of DAIC's continuing Thought Leadership Series, this month Editorial Director Melinda Taschetta-Millane sits ...

Home July 30, 2024
Home
News | Cardiovascular Clinical Studies

July 25, 2024 — BioCardia, Inc., a global leader in cellular and cell-derived therapeutics for the treatment of ...

Home July 25, 2024
Home
News | Cardiovascular Clinical Studies

July 18, 2024 — Elucid, a pioneering AI medical technology company providing physicians with imaging analysis software ...

Home July 18, 2024
Home
News | Cardiovascular Clinical Studies

July 10, 2024 — CellProthera, a private company specializing in cell-based therapies for repairing ischemic tissues, and ...

Home July 10, 2024
Home
News | Cardiovascular Clinical Studies

July 9, 2024 — Microbot Medical Inc. announced the completion of the first procedure in a patient utilizing its LIBERTY ...

Home July 09, 2024
Home
News | Cardiovascular Clinical Studies

June 26, 2024 — Semaglutide, a medication initially developed for type 2 diabetes and obesity, significantly improves ...

Home June 26, 2024
Home
News | Cardiovascular Clinical Studies

June 21, 2024 — Lexicon Pharmaceuticals, Inc. announced that the peer-reviewed Journal of the American College of ...

Home June 21, 2024
Home
News | Cardiovascular Clinical Studies

June 20, 2024 — Microbot Medical Inc. announced its agreement with Brigham and Women’s Hospital (BWH), a leading ...

Home June 20, 2024
Home
News | Cardiovascular Clinical Studies

June 20, 2024 — A programming algorithm, being tested by HonorHealth Research Institute for those patients with new or ...

Home June 20, 2024
Home
Subscribe Now